HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
NCT06849492 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2025-02-27
Summary
To explore the efficacy and safety of treatment for recurrent and metastatic advanced first-line triple-negative breast cancer guided by cell surface protein-based subtyping (HIM).
Conditions
- Advanced Triple Negative Breast Cancer
Interventions
- DRUG
-
Camrelizumab
PD-1 inhibitor
- DRUG
-
chemotherapy
- DRUG
-
SKB264
Trop2-ADC
- DRUG
-
Anti-angiogenic TKI
Sponsors & Collaborators
-
Fudan University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-01
- Primary Completion
- 2027-12-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
NCT04067102 ·Status: WITHDRAWN ·Phase: NA
-
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
NCT04676997 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06279364 ·Status: RECRUITING ·Phase: PHASE3
-
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
NCT04913571 ·Status: UNKNOWN ·Phase: PHASE2
-
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
NCT04517292 ·Status: UNKNOWN ·Phase: PHASE2
-
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
NCT07182721 ·Status: RECRUITING ·Phase: PHASE2
-
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
NCT06387628 ·Status: RECRUITING ·Phase: PHASE2
-
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
NCT06731153 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
NCT06786026 ·Status: RECRUITING ·Phase: PHASE2
-
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
NCT07139470 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
NCT06754059 ·Status: RECRUITING
-
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
NCT07071337 ·Status: RECRUITING ·Phase: PHASE3
-
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
NCT02658214 ·Status: COMPLETED ·Phase: PHASE1
-
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
NCT05085626 ·Status: UNKNOWN ·Phase: PHASE2
-
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
NCT05445908 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
NCT04927884 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
NCT06401005 ·Status: RECRUITING ·Phase: PHASE2
-
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
NCT05088057 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
NCT05681728 ·Status: UNKNOWN ·Phase: PHASE2
-
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
NCT07255612 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
NCT04129996 ·Status: UNKNOWN ·Phase: PHASE2
-
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
NCT05429294 ·Status: UNKNOWN ·Phase: PHASE2